| Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels M Colleoni, A Rocca, MT Sandri, L Zorzino, G Masci, F Nole, G Peruzzotti, ... Annals of Oncology 13 (1), 73-80, 2002 | 587 | 2002 |
| Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results L Buscarini, E Buscarini, M Di Stasi, D Vallisa, P Quaretti, A Rocca European radiology 11, 914-921, 2001 | 440 | 2001 |
| Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer S Dellapasqua, F Bertolini, V Bagnardi, E Campagnoli, E Scarano, ... Journal of clinical oncology 26 (30), 4899-4905, 2008 | 341 | 2008 |
| CT Perfusion for the Monitoring of Neoadjuvant Chemotherapy and Radiation Therapy in Rectal Carcinoma: Initial Experience1 M Bellomi, G Petralia, A Sonzogni, MG Zampino, A Rocca Radiology 244 (2), 486-493, 2007 | 264 | 2007 |
| Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society … D Cardinale, F Ciceri, R Latini, MG Franzosi, MT Sandri, M Civelli, ... European journal of cancer 94, 126-137, 2018 | 236 | 2018 |
| Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects M Colleoni, L Orlando, G Sanna, A Rocca, P Maisonneuve, G Peruzzotti, ... Annals of Oncology 17 (2), 232-238, 2006 | 231 | 2006 |
| A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy X León, R Hitt, M Constenla, A Rocca, R Stupp, AF Kovács, N Amellal, ... Clinical Oncology 17 (6), 418-424, 2005 | 231 | 2005 |
| Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer L Orlando, A Cardillo, R Ghisini, A Rocca, A Balduzzi, R Torrisi, ... BMC cancer 6, 1-8, 2006 | 160 | 2006 |
| Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional … R Torrisi, A Balduzzi, R Ghisini, A Rocca, L Bottiglieri, F Giovanardi, ... Cancer chemotherapy and pharmacology 62, 667-672, 2008 | 159 | 2008 |
| Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. C Tondini, M Zanini, F Lombardi, C Bengala, A Rocca, R Giardini, ... Journal of clinical oncology 11 (4), 720-725, 1993 | 149 | 1993 |
| Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients L Licitra, S Marchini, S Spinazzè, A Rossi, A Rocca, C Grandi, R Molinari Cancer 68 (9), 1874-1877, 1991 | 145 | 1991 |
| Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer L Orlando, A Cardillo, A Rocca, A Balduzzi, R Ghisini, G Peruzzotti, ... Anti-cancer drugs 17 (8), 961-967, 2006 | 140 | 2006 |
| Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors M Colleoni, I Minchella, G Mazzarol, F Nole, G Peruzzotti, A Rocca, ... Annals of oncology 11 (8), 1057-1060, 2000 | 139 | 2000 |
| Association between hepatitis C virus and non-Hodgkin’s lymphoma, and effects of viral infection on histologic subtype and clinical course D Vallisa, R Bertè, A Rocca, G Civardi, F Giangregorio, B Ferrari, G Sbolli, ... The American journal of medicine 106 (5), 556-560, 1999 | 133 | 1999 |
| Androgen receptor signaling pathways as a target for breast cancer treatment E Pietri, V Conteduca, D Andreis, I Massa, E Melegari, S Sarti, ... Endocr Relat Cancer 23 (10), R485-R498, 2016 | 126 | 2016 |
| Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors A Farolfi, E Melegari, M Aquilina, E Scarpi, T Ibrahim, R Maltoni, S Sarti, ... Heart 99 (9), 634-639, 2013 | 126 | 2013 |
| Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer A Rocca, A Farolfi, S Bravaccini, A Schirone, D Amadori Expert opinion on pharmacotherapy 15 (3), 407-420, 2014 | 121 | 2014 |
| Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy SP Hong, TE Chan, Y Lombardo, G Corleone, N Rotmensz, S Bravaccini, ... Nature communications 10 (1), 3840, 2019 | 117 | 2019 |
| Breast cancer vaccines: a clinical reality or fairy tale? G Curigliano, G Spitaleri, E Pietri, M Rescigno, F De Braud, A Cardillo, ... Annals of Oncology 17 (5), 750-762, 2006 | 112 | 2006 |
| Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease M Colleoni, N Rotmensz, G Peruzzotti, P Maisonneuve, L Orlando, ... Annals of oncology 17 (10), 1497-1503, 2006 | 107 | 2006 |
